Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19.

Anavex President & CEO Christopher U. Missling, PhD, will be presenting preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19, 2017.

May 17-19, 2017 | Turnberry Isle Miami Hotel  | Aventura, Florida

Antiepileptic Drug Trials XIV Conference | May 2017
Friday, May 19, 2017
3:10pm ET
ANAVEX 2-73, A Clinical Candidate for Neurodevelopmental Disorders
Christopher Missling, PhD, Anavex Life Sciences Corp.  

Share this: